Ovarian cancer treatment flaws have been exposed during a recent study, according to an article in the New York Times. The study was conducted by Dr. Robert E. Bristow, director of gynecologic oncology at the University of California, Irvine. The study revealed a high percentage of ovarian cancer patients whose lives are cut short because they don’t receive the right treatments. The story emphasizes the need for cancer patients to see specialists who can guide them to treatments that will extend their lives.

Unfortunately, too many GIST patients are in the same situation, which is why the Life Raft Group urges them to see specialists and undergo mutational testing that can guide them to targeted treatments.  You can find our listing of GIST specialists here.

Dr. Bristow presented his findings on Monday at a meeting of the Society of Gynecologic Oncology in Los Angeles. The following statement about ovarian cancer stands out:

“If we could just make sure that women get to the people who are trained to take care of them, the impact would be much greater than that of any new chemotherapy drug or biological agent.”

Read the full article at the New York Times. Do you have any thoughts on the current state of ovarian cancer treatment? Share your comments in the section below.

LRG Contributor
Author: LRG Contributor